Investigational Drug Details
| Drug ID: | D500 |
| Drug Name: | Medetomidine |
| Synonyms: | |
| Type: | small molecule |
| DrugBank ID: | DB11428 |
| DrugBank Description: | Medetomidine is a synthetic compound used as a surgical anesthetic and analgesic. It is normally found as its hydrochloride salt, medetomidine hydrochloride. Medetomidine is an intravenously available alpha-2 adrenergic agonist. The drug has been developed by Orion Pharma. In the United States, it is currently approved for its veterinary use in dogs and distributed by Pfizer Animal Health. In Canada, medetomidine is distributed by Novartis Animal Health. The marketed product is a racemic mixture of two stereoisomers from which dexmedetomidine is the main active isomer. |
| PubChem ID: | 68602 |
| CasNo: | 86347-14-0 |
| Repositioning for NAFLD: | Yes |
| SMILES: | CC(C1=CN=CN1)C1=CC=CC(C)=C1C |
| Structure: |
|
| InChiKey: | CUHVIMMYOGQXCV-UHFFFAOYSA-N |
| Molecular Weight: | 200.2795 |
| DrugBank Targets: | |
| DrugBank MoA: | |
| DrugBank Pharmacology: | |
| DrugBank Indication: | |
| Targets: | |
| Therapeutic Category: | |
| Clinical Trial Progress: | |
| Latest Progress: |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0994 | NCT01780454 | PHASE1|PHASE2 | COMPLETED | YES | 2013-03 | 2021-04-19 | Details |
| L3639 | NCT01614769 | PHASE1 | COMPLETED | YES | 2012-07-18 | 2018-08-16 | Details |
| L4261 | NCT02906917 | PHASE3 | COMPLETED | YES | 2016-09-20 | 2019-11-13 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title |
|---|